Heme oxygenase–1 (HO-1, encoded by HMOX1) dampens inflammatory reactions via the catabolism of heme into CO, Fe, and biliverdin. We report that expression of HO-1 dictates the pathologic outcome of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). Induction of EAE in Hmox1+/− C57BL/6 mice led to enhanced CNS demyelination, paralysis, and mortality, as compared with Hmox1+/+ mice. Induction of HO-1 by cobalt protoporphyrin IX (CoPPIX) administration after EAE onset reversed paralysis in C57BL/6 and SJL/J mice and disease relapse in SJL/J mice. These effects were not observed using zinc protoporphyrin IX, which does not induce HO-1. CoPPIX protection was abrogated in Hmox1+/− C57BL/6 mice, indicating that CoPPIX acts via HO-1 to suppress EAE progression. The protective effect of HO-1 was associated with inhibition of MHC class II expression by APCs and inhibition of Th and CD8 T cell accumulation, proliferation, and effector function within the CNS. Exogenous CO mimicked these effects, suggesting that CO contributes to the protective action of HO-1. In conclusion, HO-1 or exposure to its end product CO counters autoimmune neuroinflammation and thus might be used therapeutically to treat MS.

Introduction

MS is a presumed autoimmune disorder that targets the CNS (1). Neuroinflammatory lesions associated with MS progression are triggered upon interaction of activated pathogenic Th cells with APCs within the CNS. This leads to the generation of a proinflammatory response that causes irreversible oligodendrocyte injury, neuron demyelination, and eventually axonal loss, the main pathologic hallmarks of MS (2–4).

The clinical course of MS is, in most cases, associated with transitory episodes of remission (2), suggesting that regulatory mechanisms must operate to counter neuroinflammation and/or to promote neuron regeneration. Such mechanisms may involve, but are most probably not limited to, the participation of regulatory T cells (5, 6). We hypothesized that expression of “protective genes” (5, 7) might also promote MS remission. One candidate is heme oxygenase–1 (HMOX1/HO-1), a prototypical cytoprotective and antiinflammatory stress-responsive gene (reviewed in refs. 5, 8) that can be upregulated by pathogenic Th cells (5, 6). We hypothesized that expression of “protective genes” (5, 7) might also promote MS remission. One candidate is heme oxygenase–1 (HMOX1/HO-1), a prototypical cytoprotective and antiinflammatory stress-responsive gene (reviewed in refs. 5, 8) would suggest that HO-1 acts in a protective manner via the generation of CO. It is likely, however, that other end products of HO-1 activity such as biliverdin (16) and/or free Fe (by upregulating heavy chain ferritin expression, ref. 17; or cellular Fe efflux pumps, ref. 18) may exert similar effects.

Whether HO-1 modulates the pathogenesis of autoimmune neuroinflammation remained to be established, because both protective (19) and deleterious (20) effects of chemical HO-1 modulators have been demonstrated in EAE. Using HO-1–deficient (Hmox1–/–) mice, we demonstrate that expression of HO-1 inhibited inflammation, demyelination, and paralysis, preventing mortality associated with the development of EAE. We also provide evidence that induction of HO-1 using protoporphyrins modulated ongoing autoimmune neuroinflammation, thereby reverting paralysis and leading to disease remission in mice with previously established EAE. Exogenous CO mimicked this effect, which suggests that this end product of heme degradation contributes to the protective action of HO-1. Suppression of EAE was associated with inhibition of (a) leukocyte accumulation in the CNS, (b) MHC class II expression by CNS APCs, and (c) pathogenic Th cell proliferation and effector function.

Results

Expression of HO-1 counters the pathogenesis of EAE. Given that HO-1 expression in the CNS is associated with the development of both EAE and MS (10, 19, 20), and based on the well-established protective effect of HO-1 (reviewed in refs. 5, 8), we hypothesized that HO-1 might modulate the pathogenesis of EAE. When immunized with the myelin oligodendrocyte glycoprotein peptide 35–55 (MOG35–55), Hmox1+/− C57BL/6 mice developed a more severe form of EAE than did wild-type (Hmox1+/+) C57BL/6 mice (Figure 1A and Table 1), with 75% mortality in Hmox1+/− mice compared with 19% mortality in Hmox1+/+ controls (P = 0.0024; Table 1).

We tested whether induction of HO-1 by metal protoporphyrins would arrest EAE progression in Hmox1+/+ C57BL/6 mice.
Induction of HO-1 expression and function by administration of cobalt protoporphyrin IX (CoPPIX) after EAE onset (i.e., disease incidence, 37%; mean clinical score, 0.7 ± 0.1) reversed paralysis and led to complete disease remission in 66.6% of mice compared with controls treated with vehicle (PBS) or zinc protoporphyrin IX (ZnPPIX; Figure 1B and Table 2). To address whether similar effects would occur in other mouse strains, EAE was induced in SJL/J mice by immunization with the proteolipid protein peptide 139–151 (PLP139–151) (open circles; n = 21) versus Hmox1−/− (filled circles; n = 8) mice. (B and C) C57BL/6 (B) or SJL/J (C) mice, randomized 2 days after EAE onset, were treated daily with PBS (open squares; n = 10–15), CoPPIX (filled squares; n = 10–14), or ZnPPIX (gray squares; n = 10–14). (D) C57BL/6 Hmox1−/− mice were treated as in B. Hmox1 mRNA and protein expression in the CNS were assessed by quantitative RT-PCR and Western blotting, respectively. Hmox1 mRNA expression is shown as mean number of Hmox1 per HPRT mRNA molecules ± SD. (E) EAE was induced in C57BL/6 Hmox1+/+ (open circles; n = 12) and Hmox1−/− (filled circles; n = 3) mice treated with CoPPIX as in B. (F) EAE was induced in C57BL/6 Hmox1−/− mice, randomized 10–12 days after immunization, and exposed to CO (450 ppm; dark gray squares; n = 20) or not (light gray squares; n = 22). Shaded areas indicate periods of designated treatment. *P < 0.05; **P < 0.01.

Figure 1
HO-1 and CO suppress EAE progression. EAE was induced, and disease severity was scored daily thereafter. Clinical scores are shown as mean ± SEM. (A) Progression of EAE in C57BL/6 Hmox1+/+ (open circles; n = 21) versus Hmox1−/− (filled circles; n = 8) mice. (B and C) C57BL/6 (B) or SJL/J (C) mice, randomized 2 days after EAE onset, were treated daily with PBS (open squares; n = 10–15), CoPPIX (filled squares; n = 10–14), or ZnPPIX (gray squares; n = 10–14). (D) C57BL/6 Hmox1−/− mice were treated as in B. Hmox1 mRNA and protein expression in the CNS were assessed by quantitative RT-PCR and Western blotting, respectively. Hmox1 mRNA expression is shown as mean number of Hmox1 per HPRT mRNA molecules ± SD. (E) EAE was induced in C57BL/6 Hmox1+/+ (open circles; n = 12) and Hmox1−/− (filled circles; n = 3) mice treated with CoPPIX as in B. (F) EAE was induced in C57BL/6 Hmox1−/− mice, randomized 10–12 days after immunization, and exposed to CO (450 ppm; dark gray squares; n = 20) or not (light gray squares; n = 22). Shaded areas indicate periods of designated treatment. *P < 0.05; **P < 0.01.

Table 1
HO-1 controls the pathogenesis of EAE

<table>
<thead>
<tr>
<th>Genotype</th>
<th>n</th>
<th>Incidence (%)</th>
<th>Onset (d ± SEM)</th>
<th>Maximal clinical score (± SEM)</th>
<th>Mortality (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hmox1−/−</td>
<td>8</td>
<td>95</td>
<td>16 ± 1.01</td>
<td>2.3 ± 0.35 (day 26)</td>
<td>19.04</td>
</tr>
<tr>
<td>Hmox1+/+</td>
<td>21</td>
<td>100</td>
<td>15.5 ± 0.73</td>
<td>4.5 ± 0.37 (day 40)</td>
<td>75%</td>
</tr>
</tbody>
</table>

*P = 0.0053 versus Hmox1−/−, **P = 0.002 versus Hmox1+/+.
and CD45<sup>hi</sup>CD11b<sup>+</sup> macrophages (M<sub>φ</sub>; Figure 3A and Supplemental Figure 2). Induction of HO-1 by CoPPIX decreased by 80% ± 6% the total number of leukocytes within the CNS compared with PBS-treated controls (P < 0.001; Figure 3A). This decrease was reflected by an 83% ± 7% decrease in Th cells (P < 0.001) and a 67% ± 17% decrease in CD8<sup>+</sup> T cells (P < 0.001) compared with PBS-treated controls (Figure 3A). These data demonstrate that HO-1 induction after EAE onset significantly decreases the number of CNS leukocytes and the formation of inflammatory foci within the CNS.

We tested whether HO-1 interfered with the activation, proliferation, and/or acquisition of effector function by CNS-infiltrating Th cells. Induction of HO-1 by CoPPIX reduced by 57% ± 2% the frequency of Th cells undergoing cell cycle progression (BrdU<sup>+</sup>; P = 0.028) and by 51.5% ± 34% that of Th cells expressing IL-10 (Figure 3B) was not modulated by HO-1, an effect that should contribute to suppressing EAE progression as well. The frequency of forkhead box p3–positive (Foxp<sup>3</sup>) regulatory T cells within the CNS was not modulated by HO-1 induction (Figure 3B and Supplemental Figure 3C), suggesting that the protective effect of HO-1 may act independently of regulatory T cells.

We tested whether expression of Th cell activation surface markers, including CD69, CD25, CD44, and CD62 ligand (CD62L), were modulated by HO-1 induction. We found that this was not the case for the frequency of Th cells expressing these markers (Supplemental Figure 4) or for their relative level of expression (data not shown).

The frequency of CNS-infiltrating CD8<sup>+</sup> T cells undergoing cell cycle progression (BrdU<sup>+</sup>) was reduced by 55% ± 21% when HO-1 was induced compared with vehicle-treated controls (P = 0.028; Figure 3C and Supplemental Figure 3D), an effect that should contribute to suppressing EAE progression (2–4). Induction of HO-1 did not modulate IFN-γ or TNF-α expression by CNS-infiltrating CD8<sup>+</sup> T cells (Figure 3C).

### Table 2

<table>
<thead>
<tr>
<th>Strain</th>
<th>Treatment</th>
<th>n</th>
<th>Maximal clinical score (± SEM)</th>
<th>Mortality (%</th>
<th>Remission (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C57BL/6</td>
<td>PBS</td>
<td>15</td>
<td>2.33 ± 0.44 (day 28)</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>C57BL/6</td>
<td>CoPPIX</td>
<td>14</td>
<td>0.84 ± 0.21 (day 15)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0</td>
<td>66.6&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>C57BL/6</td>
<td>ZnPPIX</td>
<td>14</td>
<td>2.28 ± 0.22 (day 18)</td>
<td>20&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0</td>
</tr>
<tr>
<td>SJL/J</td>
<td>PBS</td>
<td>10</td>
<td>2.3 ± 0.36 (day 20)</td>
<td>0</td>
<td>11.1</td>
</tr>
<tr>
<td>SJL/J</td>
<td>CoPPIX</td>
<td>10</td>
<td>1.2 ± 0.45 (day 16)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0</td>
<td>75.0&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>SJL/J</td>
<td>ZnPPIX</td>
<td>10</td>
<td>2.5 ± 0.44 (day 17)</td>
<td>0</td>
<td>11.1</td>
</tr>
<tr>
<td>C57BL/6</td>
<td>Air</td>
<td>10</td>
<td>3.09 ± 0.26 (day 23)</td>
<td>22.7</td>
<td>0</td>
</tr>
<tr>
<td>C57BL/6</td>
<td>CO</td>
<td>10</td>
<td>1.9 ± 0.69 (day 30)&lt;sup&gt;f&lt;/sup&gt;</td>
<td>15&lt;sup&gt;g&lt;/sup&gt;</td>
<td>0</td>
</tr>
</tbody>
</table>

<sup>a</sup>P = 0.0117 versus PBS-treated C57BL/6. <sup>b</sup>P < 0.05 versus PBS- and ZnPPIX-treated C57BL/6. <sup>c</sup>P = NS. <sup>d</sup>P = 0.0278 versus PBS-treated SJL/J. <sup>e</sup>P < 0.05 versus PBS- and ZnPPIX-treated SJL/J. <sup>f</sup>P = 0.009 versus air-treated C57BL/6.
HO-1 induction did not interfere with priming of naive myelin-reactive Th cells in vivo.

Exposure of C57BL/6 mice to CO inhibited by 71% ± 5% the proliferative response of myelin-reactive Th cells compared with control mice exposed to air under similar flow conditions (P = 0.0016; Figure 4C). In the same experimental setting, CO inhibited TNF-α secretion by 40% ± 2% (P = 0.0029) but failed to inhibit IFN-γ secretion (Figure 4D). This suggests that the immunomodulatory effect of CO may be more restricted than that of HO-1 induction.

**HO-1 expression in APCs inhibits myelin-reactive Th cell proliferation.** We reasoned that inhibition of Th cell proliferation could result from induction of HO-1 expression in Th cells (22, 23) and/or in APCs (24). To test the first possibility, Th cells were purified from MOG35-55-immunized mice in which HO-1 was induced. Proliferation of Th cells from CoPPIX-treated mice was not significantly inhibited in the presence of APCs isolated from PBS- or ZnPPIX-treated controls (Figure 4F). This suggests that HO-1 expression in Th cells is not sufficient per se to suppress Th cell proliferation.

That the antiproliferative effect of HO-1 is exerted via APCs is suggested by the following set of observations. Proliferation of purified myelin-reactive Th cells from immunized but otherwise untreated mice was inhibited by 65% ± 7% in the presence of purified APCs from immunized but otherwise untreated mice compared with DCs or B cells isolated from control PBS- or ZnPPIX-treated controls (Figure 4A). Moreover, HO-1 induction did not affect the proliferative response of draining lymph node Th cells to concanavalin A (ConA; Supplemental Figure 5A) nor did it reduce Th cell numbers in draining lymph nodes (data not shown).

The same experimental system, induction of HO-1 suppressed secretion of TNF-α by 64% ± 2% (P < 0.001), IFN-γ by 75% ± 2% (P < 0.001), and IL-12/p40 by 61% ± 16% (P < 0.01) compared with controls (Figure 4B). This suggests that HO-1 suppresses the differentiation of primed myelin-reactive Th cells toward a pathogenic effector phenotype characterized by the secretion of proinflammatory cytokines.

To assess whether suppression of Th cell reactivation in vitro was due to defective priming of naive myelin-reactive Th cells in vivo, draining lymph node Th cells (>98% CD4+ cells) were isolated 7 days after immunization and rechallenged in vitro with MOG35-55 in the presence of naive APCs (<2% CD4+). Proliferation of myelin-reactive Th cells from CoPPIX-treated mice was similar to that of control mice (Supplemental Figure 5A), suggesting that HO-1 and CO suppress myelin-reactive Th cell reactivation. We hypothesized that HO-1 induction might interfere with the reactivation of primed myelin-reactive Th cells that occurs in the CNS during the development of EAE and presumably also occurs in MS patients. Induction of HO-1 by CoPPIX reduced myelin-reactive Th cell proliferation by 60.5% ± 3% compared with vehicle- or ZnPPIX-treated controls (P < 0.001; Figure 4A). Moreover, HO-1 induction did not affect the proliferative response of draining lymph node Th cells to concanavalin A (ConA; Figure 4A).
HO-1 suppresses MHC class II expression in activated APCs. To evaluate further the impact of HO-1 in APC function, draining lymph node DCs from immunized C57BL/6 mice were analyzed by flow cytometry. Induction of HO-1 by CoPPIX reduced by 39% ± 12% MHC class II expression in DCs (CD11c+) compared with controls (P < 0.001; Figure 6A). This effect was specific to MHC class II, as expression of CD40, CD80, and CD86 were not significantly affected (Supplemental Figure 6A). Induction of HO-1 did not alter the frequency or total number of DCs in the draining lymph nodes of immunized mice (data not shown). Exogenous CO inhibited by 24% ± 8% MHC class II expression in DCs compared with air-treated controls (P = 0.0011; Figure 6A). This effect was specific to MHC class II, as CO failed to inhibit the expression of CD40, CD80, or CD86 (Supplemental Figure 6B).

To test whether HO-1 and/or CO would affect other APC populations involved in the pathogenesis of EAE (26, 27), MHC class II expression was analyzed in microglia (CD45<sup>-</sup>CD11b<sup>+</sup>) and CNS-infiltrating Mφ (CD45<sup>high</sup>CD11b<sup>+</sup>) of C57BL/6 mice with established EAE. Induction of HO-1 starting 2 days after disease onset (approximately 40% EAE incidence) reduced MHC class II expression by 44% ± 13% in microglia (P < 0.05; Figure 6C) and by 47% ± 24% in CNS-infiltrating Mφ (P < 0.05; Figure 6D) compared with controls.

MHC class II–expressing cells in the CNS of mice with established EAE was confined to the perivascular area and associated primarily with CNS-infiltrating leukocytes, i.e., Mφ (Figure 6, E and F). Low-level MHC class II expression was also detected in the parenchyma, presumably associated with microglia (data not shown). Induction of HO-1 by CoPPIX reduced MHC class II expression in both perivascular leukocytes and microglia (Figure 6, E and F), confirming similar observations made by flow cytometry.

To address further the mechanism by which HO-1 suppressed MHC class II expression in CNS APCs, we tested whether induction of HO-1 in microglial BV2 cells would inhibit MHC class II expression. When stimulated in vitro with IFN-γ, microglial BV2 cells upregulated the expression of MHC class II (Figure 7, A and B). Induction of HO-1 by CoPPIX inhibited by 27% ± 7% MHC class II expression compared with controls (P < 0.05; Figure 7A). Exposure to CO mimicked this effect, inhibiting by 20% ± 7% MHC class II expression compared with air-treated controls (P < 0.05; Figure 7B). Induction of HO-1 or exposure to CO had no effect on CD40, CD80, or CD86 expression in BV2 cells (data not shown). Induction of HO-1 inhibited IFN-γ–driven phosphorylation of STAT-1 without affecting STAT-1 expression (Figure 7C). Induction of MHC class II transcription activator (CIITA) mRNA expression by IFN-γ was inhibited by 30% ± 11% compared with controls (P < 0.05; Figure 7D). Given the central role of STAT-1 phosphorylation and CIITA
provide evidence that endogenous HO-1 suppressed both the pathologic outcome of EAE, a well-established model of MS. We hypothesized that the protective gene HO-1 may control the severity and the mortality associated with the development of this neuroinflammatory disease (5, 7). We refer to those genes as protective (7) and in APCs (28) (reviewed in ref. 29), the inhibitory effect of HO-1 over MHC II expression in these cells might be explained by its ability to suppress STAT-1 phosphorylation and CIITA expression.

Discussion

There are several genes that can limit the deleterious effects of inflammation and thus counter the pathogenesis of inflammatory diseases (5, 7). We refer to those genes as protective (7) and hypothesized that the protective gene HO-1 may control the pathologic outcome of EAE, a well-established model of MS. We provide evidence that endogenous HO-1 suppressed both the severity and the mortality associated with the development of this neuroinflammatory disease (Figure 1A and Table 1). Upregulation of HO-1 by CoPPIX acted therapeutically to reverse paralysis (Figure 1, B and C, and Table 2). That the therapeutic effect of CoPPIX is exerted via HO-1 is demonstrated by the observation that (a) CoPPIX induces the expression of HO-1 in the CNS of mice with EAE (Figure 1D) and (b) the protective effect of CoPPIX is abrogated in Hmox1−/− mice (Figure 1E).

CO contributes to the protective effects of HO-1, as exposure of Hmox1−/− mice to CO mimicked the protective effects of HO-1 (Figure 1F, Figure 4, C and D, Figure 6B, and Figure 7B). One would expect, however, that other end products of heme degradation, e.g., biliverdin, may act in a similar manner (30). However, biliverdin does not suppress myelin-reactive Th cell proliferation, nor does it suppress EAE progression (Supplemental Figure 7). One possible explanation may be that the protective effect of HO-1 is exerted within the CNS, which biliverdin cannot enter because of its exclusion by the blood-brain barrier.

Our data suggest that the mechanism underlying the protective effect of HO-1 is associated with a profound inhibition of leukocyte accumulation (Figure 2G and Figure 3A) and reactivation (Figure 3, B and C) within the CNS. This is suggested by the observation that HO-1 induction by CoPPIX administration after EAE onset reduced the number of inflammatory foci (Figure 2G) as well as the total number of CNS Th cells, CD8+ T cells, and Mφ (Figure 3A) and in addition suppressed the proliferation of the remaining Th and CD8+ T cells (Figure 3, B and C) infiltrating the CNS.

The antiproliferative effect of HO-1 was shown in vitro to be strictly dependent on DCs (Figure 4G) that express high levels of HO-1 (Figure 5, B and C). That a similar effect may occur in vivo to arrest EAE progression is suggested by the observation that DCs expressing high levels of HO-1 were detected in the CNS of CoPPIX-treated mice in which EAE progression was arrested (Figure 5A).

Induction of HO-1 leads to specific inhibition of MHC class II expression in APCs (28) (reviewed in ref. 29), the inhibitory effect of HO-1 over MHC II expression in these cells might be explained by its ability to suppress STAT-1 phosphorylation and CIITA expression.

Figure 5

CoPPIX induces HO-1 expression in DCs in vivo and in vitro. (A) C57BL/6 mice were randomized 2 days after EAE onset and treated daily with PBS, CoPPIX, or ZnPPIX. HO-1 and CD11c (DC) expression in spinal cords was detected by immunocytochemistry 7 days after beginning treatments and analyzed by confocal microscopy. Shown are HO-1 (left panels), CD11c (middle panels) and CD11c plus HO-1 (right panels). Original magnification, ×240. Arrows indicate positive staining. (B) Unsorted bone marrow–derived DCs (approximately 80% CD11c+) were exposed to CoPPIX or ZnPPIX, and Hmox1 mRNA and protein expression were assessed by quantitative RT-PCR and Western blotting, respectively. Hmox1 mRNA is shown as mean number of Hmox1 per HPRT mRNA molecules ± SD (n = 3 per group). (C) Bone marrow–derived DCs were purified (>98% CD11c+) and exposed to CoPPIX (50 μM for 16 hours) as in B. HO-1 (green) and CD11c (red) were detected as in A. Original magnification, ×400. (D) Expression of HO-1 was detected by Western blot in purified DCs shown in C. **P < 0.01; ***P < 0.001.
by APCs is probably sufficient to explain the protective effects of HO-1 observed herein. Another possibility would be that HO-1 promotes the accumulation of regulatory T cells and/or their activity within the CNS. This would be consistent with widespread evidence that regulatory T cells can control the pathogenesis of EAE (6, 36–38) as well as with the hypothesis that HO-1 expression may control regulatory T cell function (39). However, we observed that despite its ability to suppress ongoing EAE, induction of HO-1 failed to modulate the number of CNS-infiltrating regulatory T cells (Figure 3B). Furthermore, we also found that the number and function of regulatory T cells was unaffected in naive Hmox1−/− mice compared with Hmox1+/+ controls, suggesting that HO-1 does not influence regulatory T cell development and/or function (40).

Taken together, these data suggest that the protective effect of HO-1 in EAE does not act via modulation of regulatory T cells. That HO-1 exerts its protective effects via APCs, including CNS microglia (Figure 6, C and D), is relevant for its mechanism of action if one considers that immunomodulation within the CNS is probably required to arrest MS progression. This may explain the relative lack of efficiency in treating MS by controlling exclusively peripheral antigen presentation, which is probably not as relevant, whereas prevention of effector Th cell reactivation by CNS APCs almost certainly is (26, 31). Our finding that induction of HO-1 after EAE onset suppressed Th cell reactivation and effector function within the CNS (Figure 4B) may explain why this approach was effective in suppressing disease progression (Figure 1, B and C, and Table 2).

Our present data suggest that upon induction of HO-1 in APCs, the effector function of myelin-reactive Th cells in the CNS is modulated in a manner that suppresses their pathogenicity. This is supported by the suppression of neuroinflammatory cytokines, i.e., IFN-γ, but not neuroprotective, i.e., IL-10 (41) and TNF-α (42), cytokine expression by CNS-infiltrating Th cells (Figure 3B). Presumably, inhibition of high-level IFN-γ expression by CNS-infiltrating Th cells should promote oligodendrogenesis and thus aid to EAE remission (43). It should be noted, however, that while inhibi-

---

**Figure 6**

Induction of HO-1 and exposure to CO inhibit MHC class II expression in APCs. (A) C57BL/6 mice were treated daily with PBS, CoPPIX, or ZnPPIX (n = 4–6) starting 2 days prior to footpad immunization. Draining lymph node cells were isolated, and surface MHC class II expression was analyzed in DCs (CD11c+) by flow cytometry 8 days after immunization. Representative histograms and quantifications (mean intensity of fluorescence; MIF) are shown as mean ± SD. (B) C57BL/6 mice were exposed to air (n = 6) or CO (450 ppm; n = 7) starting 2 days prior to immunization and continuously thereafter. Draining lymph node cells were isolated, and surface MHC class II expression was assessed in DCs (CD11c+) as in A. Representative histograms and quantifications are shown as mean ± SD. (C and D) C57BL/6 mice, randomized 2 days after EAE onset, were treated daily with PBS, CoPPIX, or ZnPPIX (n = 9 per group). MHC class II expression in (C) microglia (CD45lowCD11b+) and (D) CNS-infiltrating Mφ (CD45highCD11b+) was analyzed by flow cytometry 20 days after immunization, when controls, i.e., ZnPPIX and PBS, reached maximal disease severity. Representative histograms and quantifications are shown as mean ± SD. (E and F) EAE induction and treatments were performed as in C and D. MHC class II expression was detected by immunocytochemistry and counterstained. Original magnification, ×10 (E); ×40 (F). White arrows indicate MHC class II expression. *P < 0.05; **P < 0.01.

**Figure 7**

HO-1 inhibits STAT-1 phosphorylation and CIITA expression in CNS APCs. (A and B) Expression of MHC class II in microglial BV2 cells was monitored by flow cytometry. When indicated (+), BV2 cells were exposed to CoPPIX (50 μM) or CO (250 ppm) 6 or 16 hours, respectively, before IFN-γ stimulation (50 U/ml for 24 hours). MHC class II expression is shown as fold induction versus untreated cells ± SD (n = 3–7). (C) Phosphorylated STAT-1, total STAT-1, HO-1, and β-tubulin were detected by Western blot in BV2 cells treated as in A. (D) Expression of CIITA mRNA was quantified by real-time PCR in BV2 cells treated as in A. Results are shown as mean fold induction versus untreated cells ± SD (n = 3). *P < 0.05.
bition of IFN-γ expression in CNS-infiltrating Th cells is likely to contribute to EAE regression (44), this remains to be formally established as EAE is exacerbated in IFN-γ-deficient mice (45).

One possibility not excluded by the present study is that HO-1 may prevent EAE progression not only by immunomodulation but also by its cytoprotective properties (46, 47) in the CNS, i.e., oligodendrocytes or neurons (48). Such an effect would be consistent with the observed arrest of EAE progression (49) as well as with our previous observation that cytoprotection afforded by HO-1 can prevent the rejection of transplanted organs (50).

Even with the caution necessary for extrapolating from EAE to MS, there are several independent lines of evidence suggesting that HO-1 expression affects the clinical outcome of MS. First, HO-1 is expressed in the CNS of MS patients (9). Second, HO-1 prevents the deleterious effects of inflammation in humans (51). Third, a (G1)n, microsatellite polymorphism in the human HMOXI promoter controls HO-1 inducibility and dictates the incidence of several inflammatory diseases (reviewed in ref. 52). Additional studies are needed to determine whether HO-1 functions to prevent MS progression or promote its remission.

In conclusion, we found that HO-1 suppresses the pathologic outcome of autoimmune neuroinflammation associated with the development of EAE. This effect is mediated at least in part by CO, which acts on APCs to inhibit the expression of MHC class II and presumably the reactivation of pathogenic Th cells within the CNS. We suggest that modulation of HO-1 expression or administration of CO may be a useful therapeutic strategy to treat MS patients.

Methods

Animals. C57BL/6 and SJL/J mice were maintained under specific pathogen-free conditions approved by the Animal User and Institutional Ethical Comities of the Instituto Gulbenkian de Ciencia and the Beckman Center for Molecular Medicine. Mice were used between 6 and 8 weeks of age. Hmox1+/− mice were originally generated by S.-F. Yet (Brigham and Women’s Hospital, Boston, Massachusetts, USA; ref. 53). Littermate Hmox1+/− and Hmox1−/− mice were used as controls.

Cells and reagents. Microglial BV2 cells, obtained from E. Blasi (University of Modena and Reggio Emilia, Modena, Italy), were cultured essentially as described previously (54). Recombinant mouse IFN-γ (PeproTech) was used to induce MHC class II expression in BV2 cells. MOC35−45 was synthesized at the PAN Facility of the Beckman Center for Molecular and Cellular Medicine. CoPPIX, ZnPPIX (Frontier Scientific Inc.), and biliverdin hydrochloride (MP Biomedicals) were dissolved in 0.2 N NaOH, neutralized with 0.2 N HCl, adjusted to 1 mg/ml (CoPPIX and ZnPPIX) and 10 mM biliverdin (biliverdin) with distilled water, and sterilized by filtration.

Cytokine assays. Cell culture supernatants were used to measure TNF-α, IFN-γ, and IL-12/23(p40) concentrations by ELISA according to the manufacturer’s indications (OptEIAHM; BD Biosciences — Pharmingen).

CNS leukocyte infiltration. Leukocytes were isolated from the CNS as described previously (55). The total number of CD45+th, CD11b+, CD4+, and CD8+ T cells in the CNS was assessed by flow cytometry, using a fixed number of latex beads (Beckman Coulter) coacquired with a preestablished volume of the cellular suspensions.

DCs. Bone marrow from naive mice was flushed, and single-cell suspensions were cultured (37°C; 5% CO2, 95% humidity) in RPMI 1640 (Invitrogen), 2 mM l-glutamine (Sigma-Aldrich), 100 U/ml penicillin, 100 μg/ml streptomycin (all from Invitrogen), and 1% GM-CSF conditioned medium. Medium was replaced every 48 hours until day 6 of culture, after which CD11c cells were purified as described above or remained untreated.

EAE induction and protoporphyrin treatment. Briefly, C57BL/6 and SJL/J mice were immunized subcutaneously with MOC35−45 or PLP19−151 (200 μg), respectively, emulsified in CFA (BD Diagnostics) supplemented with Mycobacterium tuberculosis (400 μg; BD Diagnostics). C57BL/6 mice received Pertussis toxin (200 ng i.v.; Sigma-Aldrich) at the time of immunization and 2 days thereafter. Clinical signs of EAE were evaluated daily and scored as follows: 0, normal; 1, limp tail; 2, partial paralysis of the hind limbs; 3, complete paralysis of the hind limbs; 4, hind-limb paralysis and forelimb weakness; 5, moribund or deceased. Protoporphyrins were administered daily (200 μl i.p., 5 mg/kg). Biliverdin was administered at 5 μM/kg every 12 hours.

Flow cytometry and antibodies. Surface markers and intracellular cytokines were detected essentially as described previously (55). Purified anti-mouse CD4 (RM4−5), CD8 (YTS169.4), CD11b (M1/70), CD11c (HL3), CD40 (3/23), CD45 (30−F11), CD80 (16−10A1), CD86 (GL1), B220 (RA3−6B2), I−Aγ (AF6−120.1), IL−2 (JES6−5H4), IL−10 (JES5−16E3), TNF−α (MP6−XT22), and IFN−γ (XM1G1.2; all BD Biosciences — Pharmingen) were used. Anti-FcγIII/II receptor mAbs were prepared in house from hybridoma (2.4G2) culture supernatants. Antibodies were directly conjugated to PE, allophycocyanin, or FITC.

In vivo BrdU incorporation. Mice received BrdU (50 μg/g body weight i.p. administered 4 times every 2 hours; BD Biosciences — Pharmingen). CNS leukocyte infiltrates were isolated as described above, and nuclear BrdU was detected using the FITC-labeled anti-BrdU Flow Kit according to the manufacturer’s indications (BD Biosciences — Pharmingen).

Leukocyte isolation and purification. Draining lymph node homogenates were homogenized into single-cell suspension. CD4+ and CD11c+ cells were purified using single-step anti-CD4 (L3T4) and anti-CD11c (N418) MicroBeads, respectively (Miltenyi Biotech). CD8+ and CD19+ cells were purified by 2-step labeling consisting of FITC-labeled anti-CD8 (SK1) and anti-CD19 (4G7) mAb (BD) followed by anti-FITC–conjugated MicroBeads (Miltenyi Biotech). Cells were separated using a MidiMACS magnetic isolation system (Miltenyi Biotech), and purity was assessed by flow cytometry.

MOC35−45-reactive Th cell proliferation. Draining lymph node cells were isolated from PBS-, CoPPIX-, or ZnPPIX-treated animals 8 days after footpad immunization (MOC35−45 plus CFA). Cells were plated in 96-well microtiter plates (5 × 104 cells per well) in RPMI 1640 (Invitrogen), 2 mM l-glutamine (Sigma-Aldrich), 100 U/ml penicillin, 100 μg/ml streptomycin, 10% FCS, 50 μM 2-mercaptoethanol (2-ME), 10 mM HEPES, and 1 mM sodium pyruvate (all from Invitrogen) and exposed to MOC35−45 (10 μg/ml) or concanavalin A (2 μg/ml; Sigma-Aldrich) for 72 hours at 37°C (5% CO2, 95% humidity). Cell proliferation was assessed by [3H]thymidine (1 μCi/well; GE Healthcare) incorporation during the last 6 hours of culture evaluated in a scintillation counter (Tomtec; Pharmacia).

Immunocytochemistry. Purified bone marrow–derived DCs were plated in glass coverslips (Paul Marienfeld GmbH & Co.) and fixed in acetone (10 minutes at −20°C). Rabbit anti–HO-1 polyclonal antibody (SPA895, Stressgen Biotechnologies), PE-labeled anti-CD11c mAb (HL3; BD Biosciences — Pharmingen) and FITC-labeled goat anti-rabbit polyclonal antibody (Sigma-Aldrich) were used. Slides were mounted in VECTASHIELD (Vector Laboratories), and fluorescence was detected by confocal microscopy (Leica Spectral TCS-SP2; Leica Microsystems). Images were acquired using Leica confocal software (version 2.61).

Histology. Mice were perfused with PBS followed by 10% formalin. Brain and spinal cord sections were embedded in paraffin and stained with hematoxylin and eosin or with Luxol fast blue stains, and inflammatory foci were enumerated in meninges and parenchyma as described previously (56).
Rabbit anti-HO-1 polyclonal antibody (SPA895; Stressgen Biotechnologies), biotin-labeled anti-MHC class II mAb (AF6-120.1; BD Biosciences—Pharmining), PE-labeled anti-CD11c mAb (HL3; BD Biosciences—Pharmining), and FITC-labeled goat anti-rabbit (Sigma-Aldrich) polyclonal antibody were used. HRP-conjugated streptavidin and VECTASTAIN Elite ABC kit were used according to the manufacturer’s instructions (Vector Laboratories). HRP stainings were revealed using 3,3-diaminobenzidine (Sigma-Aldrich), and tissues were counterstained with Harris hematoxylin (Sigma-Aldrich). Images were acquired using a Leica (DM.LB2) microscope (Leica Microsystems) equipped with an Evolution MP5 0.5 color camera (MediaCybernetics) and free-GIMP 2.2.10 software (http://portableapps.com/apps/graphics_pictures/gimp_portable). Fluorescence staining was detected and processed as described above.

**CO exposure.** Mice were placed in a plexiglass gastight 60-l capacity chamber and exposed continuously to CO as described previously (47). Cells (37°C, 95% humidity) were exposed to CO (250 ppm in air, 5% CO2) in a plexiglass gastight 10-l chamber (2 l/min). CO concentration was monitored using a CO analyzer (Interscan Corporation). Air controls were maintained in a similar chamber without CO.

**Western blots and antibodies.** Western blots were performed as described previously (46, 47) using anti–HO-1 (SPA896; Stressgen Biotechnologies), anti–STAT-1 (Upstate USA Inc.), and anti–phospho–STAT-1 (Upstate USA Inc.) rabbit polyclonal antibodies as well as anti–β-tubulin (Sigma-Aldrich) and anti–β-actin (Sigma-Aldrich) mouse mAbs. HRP-labeled goat anti-rabbit (31460; Pierce Biotechnology) or goat anti-mouse (31439; Pierce Biotechnology) polyclonal antibodies were used to detect the primary antibodies. HRP activity was revealed using ECL. Images were acquired using a Kodak 440CF image station.

**Real-time PCR.** Total RNA was extracted using RNeasy Protect Mini Kit (QIAGEN) according to the manufacturer’s instructions and reverse transcribed as described previously (22). HO-1 (5′-TCTCAGGGGGGT-CAGTGC-3′ and 5′-GGAGCGGTGCTGGGATG-3′, CIITA (5′-CTCTACACCTCTATGACC-3′ and 5′-GCTTCTCGTCTGGTCTTAC-3′), and hypoxanthine-guanine phosphoribosyl transferase (HPRT; 5′-GTTT-GGATACCCACGACTTGTGGT-3′ and 5′-GATTCAACCTTGGCGT-CATCTTAGGC-3′) PCR products were detected using LightCycler real-time quantitative PCR (Roche Diagnostics) as described previously (22).

**Statistics.** Significance of clinical scores significance was examined by the Mann-Whitney test. Significance of Hmox1−/− versus Hmox1+/+ mouse survival was examined by the log-rank test. Fisher’s exact test was used for analyses of disease remission. All other statistical analyses were performed using ANOVA with Bonferroni’s correction for multiple comparisons. *P < 0.05 was considered significant in all tests.

**Acknowledgments**

This work was supported primarily by a GEMI Fund AgaLinde Healthcare grant to M. Soares. Â. Chora, A. Cunha, and T.F. Pais were supported by fellowships BD/3106/2000, SFRH/BD/21558/2005, and SFRH/BPD/5554/2001, respectively, from Fundação para a Ciência e Tecnologia. R.A. Sobel was supported by NIH grant NS 046414. The authors thank Abdel Saoudi (Institut National de la Sante et de la Recherche Medicale) for essential input at the initial phase of this project and Fritz H. Bach (Harvard Medical School), Jocelyne Demengeot (Instituto Gulbenkian de Ciência), and Santiago Zelenay (Instituto Gulbenkian de Ciência) for critical reading of the manuscript. We also wish to thank Nuno Sepúlveda and Ana Cristina Paulo for support with statistical analysis, Sofia Rebelo for excellent technical support, António Sousa for building the CO exposure chambers, and Mark P. Seldon for setting up and advising with CO exposure.

Received for publication April 17, 2006, and accepted in revised form November 28, 2006.

Address correspondence to: Miguel Soares, Instituto Gulbenkian de Ciência, Rua da Quinta Grande, 6, 2780-156 Oeiras, Portugal. Phone: 351-214464520; Fax: 351-214407970; E-mail: mpsoares@igc.gulbenkian.pt.

---

impairment of MHC class II expression. *Immunology.* 1:167–178.